Market research
MRSN Mersana Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 145M
- P/E ratio
- Not available
- Analyst target
- 30.75
- Dividend yield
- Not available
- Beta
- 0.43
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US59045L1061
- Market cap
- 145M
- P/E ratio
- Not available
- Analyst target
- 30.75
- Dividend yield
- Not available
- Beta
- 0.43
About
About Mersana Therapeutics Inc
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. As of January 6, 2026, Mersana Therapeutics, Inc. operates as a subsidiary of Day One Biopharmaceuticals, Inc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MRSN discussion.
5 years, 4 months ago
Mersana Therapeutics, Inc is currently in a long term downtrend where the price is trading 31.9% below its 200 day moving average.
From a valuation standpoint, the stock is 3.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1297.3.
Mersana Therapeutics, Inc's total revenue sank by 73.8% to $11K since the same quarter in the previous year.
Its net income has dropped by 77.5% to $-29M since the same quarter in the previous year.
Finally, its free cash flow fell by 32.8% to $-18M since the same quarter in the previous year.
Based on the above factors, Mersana Therapeutics, Inc gets an overall score of 1/5.